Company Genetic Technologies Limited

Equities

GTG

AU000000GTG7

Healthcare Facilities & Services

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 01:47:11 2024-04-26 am EDT			5-day change	1st Jan Change
0.12 ^AUD	+4.35%		-14.29%	-11.11%

Apr. 19	Genetic Technologies Raising $2 Million via ADS Offering	MT
Apr. 18	Top Midday Decliners	MT

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

AUD in Million	2022	Weight	2023	Weight	Delta
EasyDNA 88.6 %	6	88.3 %	8	88.6 %	+28.28%
AffinityDNA 10.9 %	-	-	1	10.9 %	-
GeneType/Corporate 0.5 %	1	11.7 %	0	0.5 %	-94.52%

AUD in Million	2022	Weight	2023	Weight	Delta
Europe, Middle East and Africa 51.7 %	3	36.8 %	4	51.7 %	+79.69%
America and Canada 25.8 %	2	33.5 %	2	25.8 %	-1.42%
Asia Pacific 18.7 %	2	27.8 %	2	18.7 %	-13.91%
Latin America 3.7 %	0	1.9 %	0	3.7 %	+149.95%

Managers	Title	Age	Since
Simon Morriss CEO	Chief Executive Officer	-	21-01-31
Erika Spaeth CTO	Chief Tech/Sci/R&D Officer	-	15-12-31
Jerzy Muchnicki BRD	Director/Board Member	-	18-01-30
Carl Stubbings PRN	Corporate Officer/Principal	-	21-08-31

Members of the board	Title	Age	Since
Lindsay Wakefield BRD	Director/Board Member	65	14-09-23
Peter Irwin Rubinstein CHM	Chairman	-	18-01-30
Jerzy Muchnicki BRD	Director/Board Member	-	18-01-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	115,417,246	101,762,304 ( 88.17 %)	0	88.17 %

Name	Equities	%	Valuation
Morgan Stanley Capital Services LLC 0.4494 %	17,289	0.4494 %	49 965 $
RhumbLine Advisers LP 0.0972 %	3,739	0.0972 %	10 806 $
UBS Securities LLC 0.0778 %	2,994	0.0778 %	8 653 $
PEH Wertpapier AG (Germany) 0.009721 %	374	0.009721 %	1 081 $
Wells Fargo Clearing Services LLC 0.003379 %	130	0.003379 %	376 $
Veripax Financial Management LLC 0.000806 %	31	0.000806 %	90 $
Heights Capital Management, Inc. 0.000000 %	0	0.000000 %	- $

Genetic Technologies Ltd.

60-66 Hanover Street

3065, Fitzroy

+61 3 8412 7000

http://www.genetype.com

address Genetic Technologies Limited(GTG)

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Other Healthcare Facilities & Services

	1st Jan change	Capi.
GENETIC TECHNOLOGIES LIMITED	-11.11%	10.35M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services